Atopic Dermatitis Combination Therapy Targeting Staphylococcus Aureus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eczema, particularly atopic dermatitis, face challenges such as side effects from corticosteroids and the development of antibiotic resistance, along with ineffective and broad-spectrum antibiotic use that harms beneficial bacteria.
Innovation Solution
A novel composition combining an anti-inflammatory compound with a compound specifically targeting gram-positive bacterial cells, preferably Staphylococcus aureus, to reduce infections and minimize side effects by selectively targeting harmful bacteria while preserving beneficial flora.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat eczema-related infections, then bacterial infections are eliminated, but antibiotic resistance develops and beneficial bacteria are harmed
Solution Approach 1:
The patent applies local quality by designing an antibody that specifically targets gram-positive bacteria (such as Staphylococcus aureus) while leaving gram-negative bacteria and beneficial flora unaffected. This selective targeting eliminates the harmful bacteria causing eczema infections without harming beneficial bacteria, thereby preventing antibiotic resistance development while maintaining local microbial balance.
2Object-generated harmful factors
If corticosteroids are used to reduce inflammation in eczema, then skin inflammation is suppressed, but side effects such as skin atrophy and HPA axis suppression occur
Solution Approach 1:
The patent introduces an antibody as an intermediary substance that specifically binds to and neutralizes inflammatory mediators involved in eczema pathogenesis. This intermediary approach provides anti-inflammatory effects without the systemic immunosuppression and local tissue atrophy caused by corticosteroids, thereby reducing harmful side effects while maintaining therapeutic efficacy.
3Object-generated harmful factors
If high doses of corticosteroids are administered to achieve effective treatment, then inflammation control is improved, but side effects increase
Solution Approach 1:
The patent employs local quality by designing a targeted antibody therapy that specifically addresses inflammatory pathways in eczema without requiring high systemic doses. This localized, specific targeting achieves effective inflammation control at lower doses, thereby minimizing systemic side effects while maintaining therapeutic benefit.
Data Source
AI summary
The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from eczema.